Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia

International Journal of Neuropsychopharmacology

Volumn 7, Issue 2, 2004, Pages 133-142

  Suzuki, Takefumi ^a   Uchida, Hiroyuki ^a   Tanaka, Kenji F ^a   Nomura, Kensuke ^a   Takano, Harumasa ^a   Tanabe, Akira ^a   Watanabe, Koichiro ^a   Yagi, Gohei ^a   Kashima, Haruo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotics; Monotherapy; Polypharmacy; Schizophrenia

Indexed keywords

BROMPERIDOL; CHLORPROMAZINE; CLOCAPRAMINE; CLOSPIPRAMINE; EMONAPRIDE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OXYPERTINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; RISPERIDONE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; TIMIPERONE; ZOTEPINE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MALE; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL STATUS;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 3042578354     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703004012     Document Type: Article

References (44)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
2. APA (1997). Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 154 (Suppl. 4), 1-63.
3. Baldessarini RJ, Cohen BM, Teicher MH (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Archives of General Psychiatry 45, 79-91.
4. Baldessarini RJ, Katz B, Cotton P (1984). Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry 141, 748-752.
5. Buckley P, Miller A, Olsen J, Peacock WJ (2001). When symptoms persist: clozapine augmentation strategies. Schizophrenia Bulletin 27, 615-628.
6. Carpenter WT, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT (1999). Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. American Journal of Psychiatry 156, 412-418.
7. Chou WH, Yan F-X, Leon JD, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Telling C, Wedlund PJ (2000). Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. Journal of Clinical Psychopharmacology 20, 246-251.
8. Ciompi L (1980). The natural history of schizophrenia in the long term. British Journal of Psychiatry 136, 413-420.
9. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophrenia Bulletin 28, 75-84.
10. Davidson L, McGlashan TH (1997). The varied outcome of schizophrenia. Canadian Journal of Psychiatry 42, 34-43.
11. Expert Consensus Guideline Series (ECGS) (1999). Treatment of schizophrenia. Journal of Clinical Psychiatry 60 (Suppl. 11), 3-80.
12. Freudenreich O, Goff DC (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica 106, 323-330.
13. Godlesky LS, Kerler R, Barber JW, Glick JL, Kellogg E, Vieweg WVR, Yank GR (1989). Multiple versus single antipsychotic drug treatment in chronic psychosis. Journal of Nervous and Mental Disease 177, 686-689.
14. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology (pp. 217-222). Washington, DC: Department of Health, Education and Welfare.
15. Inagaki A, Fuwano S, Fukuda M, Kumada Y, JESS Study Group (2001). Prescription pattern of antipsychotic in schizophrenic inpatients treated in the national mental hospitals in Japan. Presented at the 2001 Collegium Internationale Neuro-Psychopharmacologicum (CINP) Regional Meeting Hiroshima, Japan [Abstract in English, p. 21].
16. Inagaki A, Inada T, Fujii Y, Gohei Y, Yoshio T, Nakamura H, Yamauchi K (1999). [Not available in English]. Tokyo: Seiwa Press.
17. Inderbitzin LB, Lewine RRJ, Scheller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, Vidanagama BP, Waternaux C (1994). A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. American Journal of Psychiatry 151, 1753-1759.
18. Ito C, Kubota Y, Sato M (1999). A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry and Clinical Neuroscience 53 (Suppl.), S35-S40.
19. Jones B, Lehmann HE, Saxena BM, Ban TA (1968). Treatment of chronic schizophrenic patients with haloperidol and chlorpromazine combined. Current Therapeutic Research 10, 276-278.
20. Kane J, Honigfeld G, Singer J, Melzer H, Clozaril Collaborative Study Group (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with colorpromazine. Archives of General Psychiatry 45, 789-796.
21. Kupfer DJ, Sartorius N (Eds.) (2002). The usefulness and use of second-generation antipsychotic medications. Current Opinion in Psychiatry 15 (Suppl. 1), S1-S51.
22. Lehman AF, Steinwachs DM, the coinvestigators of the PORT project (1998). Translating research into practice: the schizophrenia patient outcome research team (PORT) treatment recommendations. Schizophrenia Bulletin 24, 1-10.
23. Lerner V, Chudakova B, Kravets S, Polyakova I (2000). Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrena: a preliminary report. Clinical Neuropharmacology 23, 284-286.
24. Leslie DL, Rosenheck RA (2001). Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: Individual and facility predictors. Medical Care 39, 923-933.
25. Leslie DL, Rosenheck RA (2002). From conventional to atypical antipsychotics and back: Dynamic processes in the diffusion of new medications. American Journal of Psychiatry 159, 1534-1540.
26. McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR (1999). Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. Journal of Clinical Psychiatry 60 (Suppl. 19), 5-11.
27. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP (1999). The Texas medication algorithm project (TMAP) schizophrenia algorithms. Journal of Clinical Psychiatry 60, 649-657.
28. Procyshyn RM, Kennedy NB, Tse G, Thompson B (2001). Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Canadian Journal of Psychiatry 46, 334-339.
29. Sernyak MJ, Leslie D, Rosenheck R (2003). Use of system-wide monitoring data to compare the effectiveness of atypical neuroleptic medications. American Journal of Psychiatry 160, 310-315.
30. Shiloh Z, Zemishlany D, Aizenberg M, Radwan B, Schwartz P, Dorfman-Etrog I, Modai MK, Weizman A (1997). Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. British Journal of Psychiatry 171, 569-573.
31. Smith RC (1994). Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Archives of General Psychiatry 51, 427-429.
32. Stahl SM (1999a). Antipsychotic polypharmacy, part 1: Therapeutic option or dirty little secret? Journal of Clinical Psychiatry 60, 425-426.
33. Stahl SM (1999b). Antipsychotic polypharmacy, part 2: Tips on use and misuse. Journal of Clinical Psychiatry 60, 506-507.
34. Stahl SM (2000). Essential Psychopharmacology. Neuroscientific Basis and Practical Applications (2nd edn) (pp. 400-458). Cambridge: Cambridge University Press.
35. Suzuki T, Uchida H, Tanaka F-K, Tomita M, Tsunoda K, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H (2003). Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: An open study of dose reduction for chronic schizophrenia. International Clinical Psychopharmacology 18, 323-329.
36. Taylor D, McConnell D, McConnel H, Kerwin R (2001). The Maudsley The South London and Maudsley NHS Trust 2001 Prescribing Guidelines (6th edn) (pp. 3-48). London: Martin Dunitz.
37. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry 54, 49-55.
38. Volavka J, Cooper TB, Czobor P, Lindenmayer J-P, Citrome LL, Mohr P, Bark N (2000). High-dose treatment with haloperidol: the effect of dose reduction. Journal of Clinical Psychopharmacology 20, 252-256.
39. Waddington JL, Youssef HA, Kinsella A (1998). Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 173, 325-329.
40. Weiden PJ, Aquila R, Dalheim L, Standard JM (1997). Switching antipsychotic medications. Journal of Clinical Psychiatry 58 (Suppl. 10), 63-72.
41. Weiden PJ, Aquila R, Emanuel M, Zygmunt A (1998). Long-term considerations after switching antipsychotics. Journal of Clinical Psychiatry 59 (Suppl. 19), 36-49.
42. WHO (1992). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization.
43. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD (1999). Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Medical Care 37, AS81-AS86.
44. Yamauchi K, Baba K, Ikegami N, Miyaoka H, Kamijima K (1998). A survey of drug utilization in psychiatric hospitals in Japan: the basic analysis of the current status of prescription patterns [in Japanese]. Psychiatria et Neurologica Japonica 100, 51-67 [Abstract in English].